Announcement on Implementation Result of Shares Repurchase and Share Changes
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Implementation Result of Shares Repurchase and Share Changes
Filed with SSE · · 3 pages · Chinese
On 6ix: 6ix.com/news/announcement-on-implementation-result-of-shares-repurchase-and-share-changes-82
Release
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. on 6ix
Earlier from Nanjing King-friend Biochemical Pharmaceutical
- Announcement on Progress in Repurchasing Shares
- Announcement on Convening Performance and Cash Dividend Meeting for 2025 and Q1 2026
- Announcement on Proposing of Purchasing Liability Insurance for the Company and Directors, and Senior Management Members
- Announcement on Maturity and Redemption of "KING-FRIEND Convertible Bonds" and Delisting
- Announcement on the Conversion Results and Stock Changes of ""Jianyou Convertible Bonds"
Later from Nanjing King-friend Biochemical Pharmaceutical
- Announcement on Resolutions of the 1st Meeting of the 6th Board of Directors
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on the Subsidiary's Receipt of the U.S. FDA Approval for the Manufacturing Site Transfer Registration of Desmopressin Acetate Injection
- Announcement on Obtaining the Drug Registration Approval for Propofol Emulsion Injection by the National Medical Products Administration
- Announcement on the U.S. FDA Approval of the Subsidiary's Insulin Aspart Injection
Follow Nanjing King-friend Biochemical Pharmaceutical into a list and get an email when it puts out news.
Follow Nanjing King-friend Biochemical Pharmaceutical